口服阿昔洛韦治疗手部复发性单纯疱疹病毒2型感染。
Oral acyclovir therapy of recurrent herpes simplex virus type 2 infection of the hand.
作者信息
Gill M J, Bryant H E
机构信息
Department of Microbiology, University of Calgary, Alberta, Canada.
出版信息
Antimicrob Agents Chemother. 1991 Feb;35(2):382-3. doi: 10.1128/AAC.35.2.382.
Acyclovir was evaluated as treatment of recurrent herpes simplex virus type 2 infection of the hand in a double-blind, placebo-controlled crossover study. In nine fully evaluable patients, oral acyclovir (2 g/day in three doses for 10 days) initiated during the earliest phase of a recurrence reduced the mean durations (+/- standard deviation) of clinical symptoms from 10.1 (+/- 3.6) to 3.7 (+/- 3.0) days (P = 0.008), signs from 11.1 (+/- 3.7) to 6.2 (+/- 3.3) days (P = 0.024), and viral positivity from 5.3 (+/- 3.8) to 0.6 (+/- 1.1) days (P = 0.011).
在一项双盲、安慰剂对照的交叉研究中，对阿昔洛韦治疗复发性2型单纯疱疹病毒手部感染进行了评估。在9名可完全评估的患者中，在复发最早阶段开始口服阿昔洛韦（每日2克，分三次服用，共10天），可使临床症状的平均持续时间（±标准差）从10.1（±3.6）天缩短至3.7（±3.0）天（P = 0.008），体征的平均持续时间从11.1（±3.7）天缩短至6.2（±3.3）天（P = 0.024），病毒阳性持续时间从5.3（±3.8）天缩短至0.6（±1.1）天（P = 0.011）。
Zotero 插件